格隆汇12月23日丨生物股份(600201.SH)公布，基于对公司未来持续稳定发展的信心和长期投资价值的 认可，增强投资者信心，生物控股计划自本公告披露之日起12个月内，通过上海证券交易所系统以集中 竞价方式增持公司股份，增持总金额不低于人民币5000万元，不超过人民币10000万元（以下简称"本次 增持计划"），本次增持计划不设置固定价格、价格区间，生物控股将基于对公司股票价值的合理判 断，并根据公司股票价格波动情况及资本市场整体趋势，择机实施本次增持计划。 ...

生物股份公告，公司大股东内蒙古金宇生物控股有限公司持股1.22亿股，占11.00%，计划自2025年12月 24日至2026年12月23日通过上海证券交易所集中竞价增持公司A股，增持金额5000万元～1亿元，不设 固定价格区间，资金来源为自有及自筹，并承诺在增持计划实施期间及实施完成后法定期限内不减持所 持股份。 ...

证券之星消息，12月23日动物保健板块较上一交易日上涨0.36%，生物股份领涨。当日上证指数报收于 3919.98，上涨0.07%。深证成指报收于13368.99，上涨0.27%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出2100.59万元，游资资金净流出1797.28万元，散 户资金净流入3897.87万元。动物保健板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Core Viewpoint - Junshi Biosciences has submitted its IPO application to the Hong Kong Stock Exchange, aiming to enter the biotech sector with its innovative TIL therapies, GC101 and GC203, which show promising clinical results in treating solid tumors [1] Company Overview - Junshi Biosciences, established six years ago, focuses on innovative cell therapies and drug development for solid tumors [1] - The company has reported cumulative losses exceeding 350 million yuan from 2023 to the first half of 2025, with cash and cash equivalents at 63.635 million yuan as of June 30, 2025 [1][5] Product Pipeline - GC101, a TIL therapy, has shown an objective response rate (ORR) of 41.7% in patients with metastatic non-small cell lung cancer and 30% in advanced melanoma patients, positioning it as a potential first TIL therapy approved in China [1][3] - GC203, the world's first non-viral vector gene-modified TIL therapy, has demonstrated a 33.3% ORR in heavily pre-treated ovarian cancer patients [4] Market Potential - The global TIL therapy market is expected to reach $4.5 billion by 2035, with China's market projected to grow at a compound annual growth rate (CAGR) of 40% from 2030 to 2035, outpacing global growth [4] Financial Challenges - The company has not yet generated product sales revenue and is experiencing increasing R&D expenditures, which reached 57.62 million yuan in 2023 and are projected to rise further [5] - Junshi Biosciences faces significant cash flow pressure due to ongoing losses and rising operational costs [5] Competitive Landscape - The TIL therapy market is highly competitive, with over ten similar therapies in development globally, including Iovance's approved product, Amtagvi [6] - Junshi Biosciences must continue to build advantages in clinical progress, efficacy data, and cost control to stand out in the competitive environment [6] Regulatory Environment - Positive signals from industry policies, such as breakthrough therapy designations and conditional approval processes, are accelerating the approval of innovative cell therapies in China [6]

从资金流向上来看，当日动物保健板块主力资金净流出1.39亿元，游资资金净流入5021.79万元，散户资 金净流入8897.91万元。动物保健板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月22日动物保健板块较上一交易日上涨2.22%，生物股份领涨。当日上证指数报收于 3917.36，上涨0.69%。深证成指报收于13332.73，上涨1.47%。动物保健板块个股涨跌见下表： ...

Group 1 - The core point of the news is that Jin Yu Biological Technology Co., Ltd. has seen a stock price increase of 5.01%, reaching 15.72 yuan per share, with a trading volume of 779 million yuan and a turnover rate of 4.53%, resulting in a total market capitalization of 17.477 billion yuan [1] - The company, established on March 13, 1993, and listed on January 15, 1999, primarily engages in the research, production, and sales of veterinary biological products, with main business revenue composition being 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Group 2 - From the perspective of major fund holdings, E Fund has one fund heavily invested in Jin Yu Biological, specifically the E Fund CSI Modern Agriculture Theme ETF (562900), which increased its holdings by 19,600 shares in the third quarter, totaling 239,100 shares, accounting for 2.79% of the fund's net value, ranking as the eighth largest holding [2] - The E Fund CSI Modern Agriculture Theme ETF (562900) was established on December 2, 2021, with a latest scale of 826.209 million yuan, showing a year-to-date return of 10.69% and a one-year return of 8.05%, with a cumulative loss of 20.3% since inception [2]

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688739 证券简称：成大生物公告编号：2025-060 辽宁成大生物股份有限公司 关于部分募集资金投资项目内部投资结构调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 部分募投项目内部投资结构调整情况：为进一步优化募集资金使用效率，合理配置资源，辽宁成大生 物股份有限公司（以下简称"公司"）拟对部分募集资金投资项目（以下简称"募投项目"）的内部投资结 构进行调整。本次募投项目内部投资结构调整包含两项内容：一是公司拟终止"人用疫苗研发项目"项下 子项目"b型流感嗜血杆菌结合疫苗"（以下简称"hib疫苗"）的开发；二是针对"生物技术产品研发生产基 地项目"内部投资结构及具体金额进行优化调整，以匹配项目建设节奏与实际需求。本次调整为募投项 目内部层面的投资结构优化，不涉及募投项目投资总额、实施主体及实施地点的变更，调整后可保障相 关项目规范有序推进，与公司整体发展战略高度契合。 公司于2025年12月18日召开第五届董事会第二十五次会议，审 ...

10月28日公司发布的三季报数据显示，前三季度公司共实现营业收入10.42亿元，同比增长7.38%，实现 净利润1.61亿元，同比下降4.85%。（数据宝） 生物股份12月17日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 沪股通专用 | 3546.68 | | | 买二 | 东方财富证券股份有限公司拉萨东环路第一证券营业部 | 2955.62 | | | 买三 | 华泰证券股份有限公司昆山黑龙江北路证券营业部 | 2405.53 | | | 买四 | 中信建投证券股份有限公司杭州萍水西街证券营业部 | 2078.65 | | | 买五 | 财通证券股份有限公司宁海金融中心证券营业部 | 2042.86 | | | 卖一 | 机构专用 | | 9482.71 | | 卖二 | 沪股通专用 | | 9038.38 | | 卖三 | 中信证券股份有限公司大连分公司 | 3316.75 | | --- | --- | --- | | 卖四 | 平安证券股份有限公司深圳深南东路罗 ...

转自：证券时报 人民财讯12月17日电，12月17日龙虎榜上榜个股中，分别有11只、5只股前五大买卖营业部中出现深股 通及沪股通专用席位的身影。深沪股通净买入的个股共有8只，净买入金额最多的是深南电路，深股通 专用席位净买入1.46亿元，其次是盛新锂能、航天机电、光迅科技等，净买入金额分别为1.09亿元、 8518.00万元、6642.09万元。净卖出居前的有雪人集团、生物股份、炬光科技等，净卖出金额分别为 1.43亿元、5491.70万元、5346.98万元。 ...